As of November 6, 2026, Century Therapeutics, Inc. is a publicly traded company (Nasdaq: IPSC); its largest reported holder is RA Capital, with 9.9% on Schedule 13G of January 16, 2026, then Chen Yu (9.9%). The largest insider holding is Brent Pfeiffenberger, the chief executive and president, with 3,633,839 shares (2.0% of shares outstanding), per Form 4 of September 15, 2026 (Schedule 13G, January 16, 2026).
Is this your company?
About to sign with, pay or invest in Century Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Century Therapeutics, Inc. a real, registered company?
- Century Therapeutics, Inc. files with the SEC under CIK 1850119 (its SEC filings).
- Its shares are listed under the ticker IPSC on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Philadelphia, Pennsylvania, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Century Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Layoffs: 1 state WARN notice (latest 2025-07-01, Philadelphia PA, 72 employees).
- Leadership changes: the latest reported is Joseph Truitt, Director (Form 8-K filed 2026-09-09). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names RTW Investments (filed 2026-05-15).
Who are Century Therapeutics, Inc.'s owners and officers?
Century Therapeutics, Inc.: incorporated in Delaware; business address in Philadelphia, Pennsylvania; industry Biological Products, (No Diagnostic Substances) (Form D, 2026-09-09).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-05-15 | Rtw Investments, LP | 7.1% |
| Schedule 13G/A, 2026-05-15 | Point72 Asset Management, L.P. | 3.3% |
| Schedule 13G/A, 2026-02-17 | Point72 Asset Management, L.P. | 6.8% |
| Schedule 13G, 2026-01-16 | Ra Capital Management, L.P. | 9.9% |
| Schedule 13G, 2026-01-16 | Commodore Capital LP | 7.1% |
| Schedule 13G, 2026-01-16 | Venrock Healthcare Capital Partners Iii, L.P. | 7.1% |
| Schedule 13G, 2026-01-15 | Deep Track Capital, LP | 7.34% |
| Schedule 13G, 2026-01-15 | Chen Yu | 9.9% |
| Schedule 13G, 2026-01-05 | Point72 Asset Management, L.P. | 5.4% |
| Schedule 13G/A, 2025-11-14 | Bain Capital Life Sciences Opportunities Iii, LP | 4.1% |
Questions about who owns Century Therapeutics, Inc.
Who owns Century Therapeutics, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Century Therapeutics, Inc.: Ra Capital Management, L.P. (9.9%, Schedule 13G, filed 2026-01-16), Chen Yu (9.9%, Schedule 13G, filed 2026-01-15), Deep Track Capital, LP (7.34%, Schedule 13G, filed 2026-01-15), Rtw Investments, LP (7.1%, Schedule 13G, filed 2026-05-15) and Commodore Capital LP (7.1%, Schedule 13G, filed 2026-01-16); 1 more is listed above.
Who are the largest shareholders of Century Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Century Therapeutics, Inc. on this page are Ra Capital Management, L.P. (9.9%), Chen Yu (9.9%) and Deep Track Capital, LP (7.34%).
When did Ra Capital Management, L.P. buy into Century Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ra Capital Management, L.P. on this page is the Schedule 13G, filed 2026-01-16, reporting 9.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Century Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Century Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Century Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-09 | Joseph Truitt | Director | appointed | 2026-09-09 |
Which insiders own Century Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 3,633,839 shares (2.0% of shares outstanding) (Form 4, 2026-09-15).
- , the chief scientific officer: 1,186,019 shares (0.65% of shares outstanding), 1,175,322 held directly and 10,697 indirectly (Form 4, 2026-06-15).
- Gregory Russotti: 601,971 shares (0.33% of shares outstanding), 509,198 held directly and 92,773 indirectly (Form 4, 2026-09-15).
- , the senior vice president finance and amp: 502,641 shares (0.28% of shares outstanding) (Form 4, 2026-11-05).
- , the chief operations officer: 250,141 shares (0.14% of shares outstanding) (Form 4, 2025-06-11).
Shares outstanding: 181,075,321 as of 2026-08-03, from the company's latest SEC cover page.
How much has Century Therapeutics, Inc. raised?
No fundraising or offering filing from Century Therapeutics, Inc. is on file with us.
Keep reading
More on Century Therapeutics, Inc. and the records around it.
Century Therapeutics, Inc. elsewhere on the record
- Leadership changes Sep 2026
- 5%+ stake filings May 2026
Companies that share a holder
- Bain Capital Life Sciences Opportunities III, LP also filed stake reports on 2 other companies: CABALETTA BIO, INC. (Aug 2026), KYVERNA THERAPEUTICS, INC. (Aug 2026)
- TCG Crossover GP II, LLC also filed stake reports on 21 other companies: ALX Oncology Holdings Inc. (Aug 2026), First Tracks Biotherapeutics, Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
- Venrock Healthcare Capital Partners III, L.P. also filed stake reports on 34 other companies: Entera Bio Ltd. (Oct 2026), Lycia Therapeutics, Inc. (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
Related pages
LayoffsLeadership changes5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/century-therapeutics